Poly(POG)n loaded with recombinant human bone morphogenetic protein-2 accelerates new bone formation in a critical-sized bone defect mouse model

• Published in: Journal of orthopaedic surgery and research 2020-10, Vol.15 (1), p.471-471, Article 471
• Main Authors: Tazawa, Ryo, Uchida, Kentaro, Minehara, Hiroaki, Matsuura, Terumasa, Kawamura, Tadashi, Sekiguchi, Hiroyuki, Muneshige, Kyoko, Inoue, Sho, Inoue, Gen, Takaso, Masashi
• Format: Article
• Language: English
• Subjects: Amino acids; Animals; Bone defect; Bone growth; Bone mineral content; Bone morphogenetic protein 2; Bone Morphogenetic Protein 2 - administration & dosage; Bone Morphogenetic Protein 2 - pharmacology; Bone morphogenetic proteins; Collagen; Collagen-like peptides; Computed tomography; Defects; Discriminant analysis; Disease Models, Animal; Drug Carriers; Femur; Femur - diagnostic imaging; Femur - injuries; Femur - physiopathology; Gels; Laboratories; Male; Mice, Inbred C57BL; New bone formation; Orthopedics; Osteogenesis; Osteogenesis - drug effects; Poly(POG)n; Proteins; Radiography; Recombinant Proteins - administration & dosage; Recombinant Proteins - pharmacology; Surgery; Transforming Growth Factor beta - administration & dosage; Transforming Growth Factor beta - pharmacology; X-Ray Microtomography; Zoonoses
• ISSN: 1749-799X; 1749-799X
• DOI: 10.1186/s13018-020-01977-z

Delivery of bone morphogenetic protein-2 (BMP-2) via animal-derived absorbable collagen materials is used for the treatment of large bone defects. However, the administration of bovine proteins to humans is associated with the risk of zoonotic complications. We therefore examined the effect of combining BMP-2 with collagen-like peptides, poly(POG)n, in a critical-sized bone defect mouse model. A 2-mm critical-sized bone defect was created in the femur of 9-week-old male C57/BL6J mice. Mice were randomly allocated into one of four treatment groups (n = 6 each): control (no treatment), poly(POG)n only, 0.2 μg, or 2.0 μg BMP-2 with poly(POG)n. New bone formation was monitored using soft X-ray radiographs, and bone formation at the bone defect site was examined using micro-computed tomography and histological examination at 4 weeks after surgery. Administration of 2.0 μg of BMP-2 with poly(POG)n promoted new bone formation and resulted in greater bone volume and bone mineral content than that observed in the control group and successfully achieved consolidation. In contrast, bone formation in all other groups was scarce. Our findings suggest the potential of BMP-2 with poly(POG)n as a material, free from animal-derived collagen, for the treatment of large bone defects.